PLA2基因多态性与抗精神病药物治疗反应之间的关系:antipsychotic-naïve首发精神病患者和非依从性慢性精神病患者的研究

IF 3
Sergej Nadalin , Lena Zatković , Vjekoslav Peitl , Dalibor Karlović , Branka Vidrih , Antonia Puljić , Sanja Dević Pavlić , Alena Buretić-Tomljanović
{"title":"PLA2基因多态性与抗精神病药物治疗反应之间的关系:antipsychotic-naïve首发精神病患者和非依从性慢性精神病患者的研究","authors":"Sergej Nadalin ,&nbsp;Lena Zatković ,&nbsp;Vjekoslav Peitl ,&nbsp;Dalibor Karlović ,&nbsp;Branka Vidrih ,&nbsp;Antonia Puljić ,&nbsp;Sanja Dević Pavlić ,&nbsp;Alena Buretić-Tomljanović","doi":"10.1016/j.plefa.2023.102578","DOIUrl":null,"url":null,"abstract":"<div><p>Here we investigated whether antipsychotic treatment was influenced by three polymorphisms: rs10798059 (BanI) in the phospholipase A2 (PLA2)G4A gene, rs4375 in PLA2G6, and rs1549637 in PLA2G4C. A total of 186 antipsychotic-naïve first-episode psychosis patients or nonadherent chronic psychosis individuals (99 males and 87 females) were genotyped by polymerase chain reaction analysis/restriction fragment length polymorphism. At baseline, and after 8 weeks of treatment with various antipsychotic medications, we assessed patients’ Positive and Negative Syndrome Scale (PANSS) scores, PANSS factors, and metabolic syndrome-related parameters (fasting plasma lipid and glucose levels, and body mass index). We found that PLA2G4A polymorphism influenced changes in PANSS psychopathology, and PLA2G6 polymorphism influenced changes in PANSS psychopathology and metabolic parameters. PLA2G4C polymorphism did not show any impact on PANSS psychopathology or metabolic parameters. The polymorphisms’ effect sizes were estimated as moderate to strong, with contributions ranging from around 6.2–15.7%. Furthermore, the polymorphisms’ effects manifested in a gender-specific manner.</p></div>","PeriodicalId":94179,"journal":{"name":"Prostaglandins, leukotrienes, and essential fatty acids","volume":"194 ","pages":"Article 102578"},"PeriodicalIF":3.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between PLA2 gene polymorphisms and treatment response to antipsychotic medications: A study of antipsychotic-naïve first-episode psychosis patients and nonadherent chronic psychosis patients\",\"authors\":\"Sergej Nadalin ,&nbsp;Lena Zatković ,&nbsp;Vjekoslav Peitl ,&nbsp;Dalibor Karlović ,&nbsp;Branka Vidrih ,&nbsp;Antonia Puljić ,&nbsp;Sanja Dević Pavlić ,&nbsp;Alena Buretić-Tomljanović\",\"doi\":\"10.1016/j.plefa.2023.102578\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Here we investigated whether antipsychotic treatment was influenced by three polymorphisms: rs10798059 (BanI) in the phospholipase A2 (PLA2)G4A gene, rs4375 in PLA2G6, and rs1549637 in PLA2G4C. A total of 186 antipsychotic-naïve first-episode psychosis patients or nonadherent chronic psychosis individuals (99 males and 87 females) were genotyped by polymerase chain reaction analysis/restriction fragment length polymorphism. At baseline, and after 8 weeks of treatment with various antipsychotic medications, we assessed patients’ Positive and Negative Syndrome Scale (PANSS) scores, PANSS factors, and metabolic syndrome-related parameters (fasting plasma lipid and glucose levels, and body mass index). We found that PLA2G4A polymorphism influenced changes in PANSS psychopathology, and PLA2G6 polymorphism influenced changes in PANSS psychopathology and metabolic parameters. PLA2G4C polymorphism did not show any impact on PANSS psychopathology or metabolic parameters. The polymorphisms’ effect sizes were estimated as moderate to strong, with contributions ranging from around 6.2–15.7%. Furthermore, the polymorphisms’ effects manifested in a gender-specific manner.</p></div>\",\"PeriodicalId\":94179,\"journal\":{\"name\":\"Prostaglandins, leukotrienes, and essential fatty acids\",\"volume\":\"194 \",\"pages\":\"Article 102578\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostaglandins, leukotrienes, and essential fatty acids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0952327823000479\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins, leukotrienes, and essential fatty acids","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952327823000479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在这里,我们研究了抗精神病药物治疗是否受到三种多态性的影响:磷脂酶A2(PLA2)G4A基因中的rs10798059(BanI)、PLA2G6中的rs4375和PLA2G4C中的rs1549637。采用聚合酶链反应分析/限制性片段长度多态性对186名抗精神病药物幼稚首发精神病患者或非粘附性慢性精神病患者(99名男性和87名女性)进行基因分型。在基线时,以及在使用各种抗精神病药物治疗8周后,我们评估了患者的阳性和阴性综合征量表(PANSS)评分、PANSS因素和代谢综合征相关参数(空腹血脂和血糖水平以及体重指数)。我们发现PLA2G4A多态性影响PANSS精神病理学的变化,PLA2G6多态性影响PANSS精神病理学和代谢参数的变化。PLA2G4C多态性对PANSS精神病理学或代谢参数没有任何影响。多态性的效应大小估计为中等到强烈,贡献率在6.2-15.7%之间。此外,多态性的影响以特定性别的方式表现出来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between PLA2 gene polymorphisms and treatment response to antipsychotic medications: A study of antipsychotic-naïve first-episode psychosis patients and nonadherent chronic psychosis patients

Here we investigated whether antipsychotic treatment was influenced by three polymorphisms: rs10798059 (BanI) in the phospholipase A2 (PLA2)G4A gene, rs4375 in PLA2G6, and rs1549637 in PLA2G4C. A total of 186 antipsychotic-naïve first-episode psychosis patients or nonadherent chronic psychosis individuals (99 males and 87 females) were genotyped by polymerase chain reaction analysis/restriction fragment length polymorphism. At baseline, and after 8 weeks of treatment with various antipsychotic medications, we assessed patients’ Positive and Negative Syndrome Scale (PANSS) scores, PANSS factors, and metabolic syndrome-related parameters (fasting plasma lipid and glucose levels, and body mass index). We found that PLA2G4A polymorphism influenced changes in PANSS psychopathology, and PLA2G6 polymorphism influenced changes in PANSS psychopathology and metabolic parameters. PLA2G4C polymorphism did not show any impact on PANSS psychopathology or metabolic parameters. The polymorphisms’ effect sizes were estimated as moderate to strong, with contributions ranging from around 6.2–15.7%. Furthermore, the polymorphisms’ effects manifested in a gender-specific manner.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Prostaglandins, leukotrienes, and essential fatty acids
Prostaglandins, leukotrienes, and essential fatty acids Clinical Biochemistry, Endocrinology, Diabetes and Metabolism
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
64 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信